Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Arbutus Biopharma
Arbutus Biopharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?